arrow
R

Richard S. Finkel

St Jude Children's Research Hospital
H指数:83
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

From Burden to Breakthrough: A Roadmap to Disentangle Fatigue in Spinal Muscular Atrophy

从负担到突破:解构脊髓性肌萎缩症中疲劳感的路线图

2026-11-180
PRE
Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial

作者更正: 高剂量nusinersen治疗脊髓性肌萎缩症: 一项3期随机试验

2026-04-230
OAAI
High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial

大剂量nusinersen治疗脊髓性肌萎缩症: 一项3期随机试验

2026-02-030
OAAI
Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial

鞘内注射onasemnogene abeparvovec治疗初治的脊髓性肌萎缩症患者: 一项3期随机对照试验

2025-12-080
OAAI
Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy

开放标签IV期临床试验,评估在脊髓性肌萎缩症患儿中,在onasemnogene abeparvovec治疗后使用nusinersen的效果。

2025-11-171
OA
A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy

SAPPHIRE临床试验的简明语言摘要,该试验研究apitegromab在儿童和年轻成人脊髓性肌萎缩症患者中的应用。

2025-11-130
OAAI
Trach and treat: Safety and motor outcomes following onasemnogene abeparvovec in patients with spinal muscular atrophy and tracheostomies in the RESTORE registry

气管切开与治疗:RESTORE登记研究中,接受onasemnogene abeparvovec治疗的气管切开术患者的脊髓性肌萎缩症患者的安全性与运动结局

2025-11-110
OA
Exposure-response of serum biomarkers to vamorolone, a dissociative corticosteroidal anti-inflammatory drug, in 4-to <7-year children

vamorolone(一种解离性皮质类固醇抗炎药)对4至<7岁儿童血清生物标志物的暴露-反应关系

2025-11-010
OAAI
Designing and Implementing a Web-Based Platform for Accurate and Reliable Clinical Outcome Measures and Global Certification for Evaluating Charcot-Marie-Tooth disease

设计和实施一个基于网络的平台,用于准确和可靠的临床结局测量以及全球认证,以评估Charcot-Marie-Tooth疾病。

2025-09-010
OAAI
Long-Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons

吉温司他(Givinostat)在杜氏肌营养不良症中的长期评估及自然病史比较

2025-08-190
OA
Development of the “SMA NNE,” a short neonatal neurological examination for newborns with spinal muscular atrophy

“SMA NNE”的研制,一种用于患有脊髓性肌萎缩症新生儿的简短神经学检查方法

2025-08-190
OAAI
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial

阿皮特格罗玛ab在非行走型2型或3型脊髓性肌萎缩症中的安全性与有效性(SAPPHIRE研究):一项III期、双盲、随机、安慰剂对照试验

2025-08-130
PRE
Charcot-Marie-Tooth disease type 1E: clinical natural history and molecular impact of PMP22 variants
Brain
IF11.7
2025-06-090
PRE